Search

Your search keyword '"Baldacci S"' showing total 461 results

Search Constraints

Start Over You searched for: Author "Baldacci S" Remove constraint Author: "Baldacci S"
461 results on '"Baldacci S"'

Search Results

6. Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGFR

7. Oncogenèse pulmonaire : de l’altération moléculaire au cancer

18. Issue 2 - “Update on adverse respiratory effects of indoor air pollution”. Part 2): Indoor air pollution and respiratory diseases: Perspectives from Italy and some other GARD countries

23. Genetic and environmental influences on infant anthropometry at birth and four months of life: evidence from singleton and twin data in the HEALS and earlyFOOD projects

28. Exposure to air pollution and allergic diseases in adults

29. Air pollution exposure and prevalence of chronic respiratory diseases in Italy

30. Influence of overweight/obesity, lifestyle and grey space on asthma in Italy

31. MA07.06 Eradicating Drug Tolerant Persisters (DTPs) In EGFR-Mutated Non Small Cell Lung Cancer (NSCLC) By Targeting TROP2

32. MA07.03 Systematic Engineering of TROP2 CAR T Cell Therapy to Overcome Resistance Pathways in EGFRmutant NSCLC

34. RItA: The Italian severe/uncontrolled asthma registry

37. Outdoor air pollution and respiratory diseases: A general update and an Italian perspective

38. 1341P NRAS mutated non-small cell lung cancer (NSCLC) patients: Characteristics and outcomes

43. Longitudinal Asthma Patterns in Italian Adult General Population Samples: Host and Environmental Risk Factors

45. Indoor air pollution, physical and comfort parameters related to schoolchildren's health: Data from the European SINPHONIE study

46. Efficacité et tolérance du lorlatinib en 2e ligne ou plus chez les patients, porteurs d’un cancer bronchique non à petites cellules (CBNPC) avancé ROS1+, traités dans le cadre d’une autorisation temporaire d’utilisation (ATU), étude IFCT-1803 LORLATU

47. Efficacité et tolérance du lorlatinib en 2e ligne ou plus chez les patients, porteurs d’un cancer bronchique non à petites cellules (CBNPC) avancé ALK+, traités dans le cadre d’une autorisation temporaire d’utilisation (ATU), étude IFCT-1803 LORLATU

49. 1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort

50. 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort

Catalog

Books, media, physical & digital resources